Yesterday (March 18) PureTech Health plc announced the completion of the acquisition of its founded entity, Karuna Therapeutics, Inc., by Bristol Myers Squibb for a staggering $14 billion.
Bristol Myers Squibb has announced it has acquired Karuna Therapeutics, Inc., for a total equity value of $14 billion or $12.7 billion net of estimated cash.
Challenging target profiles can be targeted more efficiently than traditional drug discovery using Exscientia’s AI-driven precision design platform, its CEO says.
The two companies will combine real-world datasets to better understand marketing treatment with Bristol Myers Squibb’s drug in a post-marketing setting.
A $114m diversity in clinical trials initiative supported by the Bristol Myers Squibb Foundation (BMSF) and Gilead Sciences has selected 64 physicians for awards.
ConcertAI has introduced a digital trial solution informed by its collaboration with Bristol Myers Squibb to simplify patient identification, consent, IRB approval, and contract negotiations.
The pharmaceutical company and the artificial intelligence pathology specialist will focus on translational research in oncology, fibrosis, and immunology.
The pharmaceutical company has completed acquisition of Turning Point Therapeutics, a company specializing in precision medicine solutions for cancer patients.
The pharmaceutical company reportedly opted to implement the cloud software provider's clinical trial management system to help streamline its processes.
Miruna Sasu has been named president and CEO of the company, which uses RWD and analytics in advancing oncology drug development and clinical trial diversity.
The companies plan to work on developing personalized care solutions via digital pathology to come up with treatment options for patients with solid tumors.
The pharmaceutical company has announced 24 grants totaling nearly $8m USD to fuel training and support for community health workers and patient navigators.
The latest in the Diversity in Oncology series, taking place February 9, will discuss ways academia and community collaboration can narrow representation gaps.
The upcoming industry event offers attendees (in-person and virtual) a range of opportunities to learn, connect, and innovate, according to an organizer.
The organization is working to give oncology professionals the chance to hear directly from patients about their unique experiences, concerns, and hopes.
A survey commissioned by Bristol Myers Squibb reveals healthcare providers are confident that immunotherapy can positively impact earlier-stage cancers.
The pharma firm is working with five US colleges and universities onto create programming designed to boost recruitment of Black talent in the industry
The two pharma firms will partner to study the efficacy of Opdivo, paired with a SHP2 inhibitor, to treat non-small cell lung cancer with KRAS mutations.
The two organizations have joined to create the Advocacy Exchange, a virtual platform designed to bring together patients, advocates and industry leader.
The therapeutic has been approved as an adjuvant treatment for varieties of esophageal cancers in patients who have received neoadjuvant chemoradiotherapy.
OSP's free Digital Advances in Clinical Trial webinar (on December 9) will feature experts discussing recent advancements in the rapidly evolving field.
Taking place December 9, the Digital Advances in Clinical Trials webinar covers notable advances in clinical trial technology, and the future of the field.
The pharma giant and the clinical-stage drug developer will join on a pilot study investigating a candidate’s potential in overcoming resistance of a cancer drug.
